Author

Yvonne Mallory

Observed name: Y. Mallory

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Observed institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

OpenAlex ID: A5048832124

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene

2021 · Azam Ghafoor, Idrees Mian, et al. · JTO Clinical and Research Reports · 59

Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.

2020 · Raffit Hassan, Idrees Mian, et al. · Journal of Clinical Oncology · 21

Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response.

2011 · R. Hassan, E. Sharon, et al. · Journal of Clinical Oncology · 13

Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors

2021 · Madison Ballman, Shannon Swift, et al. · JTO Clinical and Research Reports · 8

Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations

2021 · Zishuo I. Hu, Markku Miettinen, et al. · Journal of Thoracic Oncology · 6

Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials

2026 · Amber F. Gallanis, Shruthi R. Perati, et al. · Annals of Surgical Oncology · 3

ASO Visual Abstract: Efficacy of Bidirectional Paclitaxel Plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single-Institution Analysis of Two Phase II Clinical Trials

2026 · Amber F. Gallanis, Shruthi R. Perati, et al. · Annals of Surgical Oncology

469: Bidirectional Paclitaxel Plus Nilotinib for Peritoneal Carcinomatosis: Phase Ii Clinical Trial Results

2025 · Shruthi R. Perati, Amber F. Gallanis, et al. · Gastroenterology

AB013. Tolerability of COVID-19 mRNA vaccines in patients with thymic epithelial tumors

2021 · Madison Ballman, Meredith J. McAdams, et al. · Mediastinum

Brief Report: Tolerability of COVID-19 Vaccines, BNT162b2 and mRNA-1273, in Patients with Thymic Epithelial Tumors.

2021 · Madison Ballman, Shannon Swift, et al.

Works count: 10

Citation count: 110

H-index: 5

I10-index: 3